Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 16 of 16 for “"Modified release"”.

  1. Modified Release of Agglomerated Nano-Particles for Pulmonary Drug Delivery

    … prepared agglomerated nanoparticles having modified drug release properties with an aerodynamic particle size suitable for delivery to the lungs.|First, a water-soluble model drug was formulated as microencapsulated dry powders using aqueous spray drying with a fluid nozzle. The spray dried …

    creighton Repository record for Modified Release of Agglomerated Nano-Particles for Pulmonary Drug Delivery (opens in a new tab)

  2. CAPSULAR DEVICES FOR ORAL MODIFIED RELEASE OF DRUGS PREPARED BY INJECTION MOLDING

    … giving rise to the expected pulsatile release performance, confirmed by in vivo data. The PhD project was undertaken aiming at improving the robustness and versatility of the ChronocapTM device as well as enhancing the industrial scalability of its manufacturing process. For this …

    milano Repository record for CAPSULAR DEVICES FOR ORAL MODIFIED RELEASE OF DRUGS PREPARED BY INJECTION MOLDING (opens in a new tab)

  3. Preparation of novel modified-release dosage forms of diclofenac sodium and ibuprofen.

    … (HPMC) were used as the principle release-retarding agents. Various excipients - lactose, Encompress®, cellulose acetate phthalate (CAP), Veegum F® and Avicel PH101® - were added in different proportions to further modify drug release. The diclofenac sodium mini-matrices (4.5 mm …

    rgu Repository record for Preparation of novel modified-release dosage forms of diclofenac sodium and ibuprofen. (opens in a new tab)

  4. Development of a Novel Vaccine Adjuvant System Utilizing an In Situ Implant System to Modified Release

    <p>Pulsatile release formulations for single dose vaccines have been studied for many years because of the advantages that they may provide to vaccine administration with a single dose instead of prime and booster shots.</p> <p>The aim of this work is to develop novel formulations based on an In …

    tenn-hsc Repository record for Development of a Novel Vaccine Adjuvant System Utilizing an In Situ Implant System to Modified Release (opens in a new tab)

  5. Συστηματική ανασκόπηση για τα βραδείας και παρατεταμένης αποδέσμευσης σκευάσματα υδροκορτιζόνης (modified-release hydrocortisone, MR-HC) στη θεραπεία της κλασικής μορφής συγγενούς υπερπλασίας των επινεφριδίων

    ΕΙΣΑΓΩΓΗ: Η Συγγενής Υπερπλασία των Επινεφριδίων (ΣΥΕ) λόγω ανεπάρκειας της 21-υδροξυλάσης είναι μία γενετική νόσος που κληρονομείται με αυτοσωματικό υπολειπόμενο χαρακτήρα. Η ΣΥΕ χαρακτηρίζεται από ανεπαρκή παραγωγή κορτικοστεροειδών και αλατοκορτικοειδών και υπερπαραγωγή επινεφριδιακών …

    athens Repository record for Συστηματική ανασκόπηση για τα βραδείας και παρατεταμένης αποδέσμευσης σκευάσματα υδροκορτιζόνης (modified-release hydrocortisone, MR-HC) στη θεραπεία της κλασικής μορφής συγγενούς υπερπλασίας των επινεφριδίων (opens in a new tab)

  6. A Study of HPMC-PEG Matrix as Drug Carrier in Spray Congealing

    … types of additives commonly used in formulating modified release dosage forms were screened for suitability as matrix material and matrix modifier for spray congealing. Screening of the additives showed that hydroxypropyl methylcellulose (HPMC) was an appropriate matrix modifier for PEG. The …

    nus Repository record for A Study of HPMC-PEG Matrix as Drug Carrier in Spray Congealing (opens in a new tab)

  7. The design and characterisation of multiparticulate lipidic systems for oral drug delivery

    … the current research was to develop a sustained release hydrophobic matrix drug delivery system utilising extrusion spheronisation. The initial formulation supplied was Sebomin® MR 100mg capsules, an oral modified release commercial product. A technological transfer was undertaken to reproduce …

    strathclyde Repository record for The design and characterisation of multiparticulate lipidic systems for oral drug delivery (opens in a new tab)

  8. Development and evaluation of oral solid dosage forms for colonic delivery of drugs for the treatment of cystinosis.

    Modified-release multiparticulate pellets have been produced by the process of extrusion and spheronisation for colon-targeted delivery of cystamine, a cysteamine derivative. Orally-ingested cysteamine formulations, used in the treatment of cystinosis, are observed to cause gastrointestinal mucosa …

    rgu Repository record for Development and evaluation of oral solid dosage forms for colonic delivery of drugs for the treatment of cystinosis. (opens in a new tab)

  9. Estimate of radiation release from MIT reactor with low enriched uranium (LEU) core during maximum hypothetical accident

    … equilibrium LEU and HEU versions of the core. Release fractions from the melted fuel to containment were established using melt test data from plate-type fuel as well as modified release fractions from NRC Regulatory Guides. The dose paths considered were the same paths used in the previous …

    mit Repository record for Estimate of radiation release from MIT reactor with low enriched uranium (LEU) core during maximum hypothetical accident (opens in a new tab)

  10. Characterisation of cysteamine prodrugs for the treatment of cystinosis and evaluation of liquid fill technology.

    Cystinosis is a rare, autosomal, recessive disease characterised by raised levels of the amino acid cystine in the cells of most organs in the body which can cause organ damage. The treatment involves the oral administration of the aminothiol, cysteamine (Cystagon(TM)), but this has an offensive …

    rgu Repository record for Characterisation of cysteamine prodrugs for the treatment of cystinosis and evaluation of liquid fill technology. (opens in a new tab)

  11. Formulation studies on cysteamine for the treatment of nephropathic cystinosis.

    … The physiochemical properties, stability and release profiles of the active cysteamine or phe conjugate from the formulations were evaluated. The suppositories released cysteamine over a 20-40 minute period with a T75 = 10-13 minutes. They were most stable at 4°C. The analysis of the …

    rgu Repository record for Formulation studies on cysteamine for the treatment of nephropathic cystinosis. (opens in a new tab)

  12. Trends in Pharmaceutical Product Development 2000-2010

    … two-thirds of the new LCM formulations were modified-release preparations. Lifecycle management is an essential part of the major pharmaceutical companies' business strategy, the importance of which was illustrated by the case study of Coreg tablets.

    helsinki Repository record for Trends in Pharmaceutical Product Development 2000-2010 (opens in a new tab)

  13. EVALUATION OF HYDROLYTIC ENZYMES IN THE DESIGN OF ORAL DRUG DELIVERY SYSTEMS

    … activity of the enzyme cellulase to improve the release performance of oral modified release dosage forms having as functional polymer hydroxypropyl methylcellulose (HPMC), a hydrophilic cellulose derivative which is substrate of the enzyme itself. Previous examples of the use of enzymes in drug …

    milano Repository record for EVALUATION OF HYDROLYTIC ENZYMES IN THE DESIGN OF ORAL DRUG DELIVERY SYSTEMS (opens in a new tab)

  14. Investigating the Hydration and Disintegration Mechanisms of Film-Coated Pharmaceutical Tablets

    … of hydration, disintegration and subsequent drug release and dissolution of a film-coated tablet are not fundamentally understood. To investigate the mechanisms, flat-faced tablets with a diameter of 13 mm and a thickness between 1.5 mm and 1.6 mm were directly compressed, and an immediate release

    cambridge Repository record for Investigating the Hydration and Disintegration Mechanisms of Film-Coated Pharmaceutical Tablets (opens in a new tab)

  15. Development of the Sustained Release Analgesic Formulations for Rodents and a Novel In Vitro Model for Parenteral Formulations with the Character of a Level A IVIVC

    … is required. However, no sustained-release analgesic product for rodents was available when we started the project in 2008. Therefore, in order to reduce the stress of frequent handling and injection as well as improve the well-being of research animals, the first objective of this …

    tenn-hsc Repository record for Development of the Sustained Release Analgesic Formulations for Rodents and a Novel In Vitro Model for Parenteral Formulations with the Character of a Level A IVIVC (opens in a new tab)

  16. NANOSUSPENSIONS-BASED ORAL DELIVERY PLATFORMS - NANODPS

    In questa tesi di dottorato è stato studiato il potenziale delle nanosospensioni (NS) come intermedi di produzione per il miglioramento della solubilità e, di conseguenza, della biodisponibilità orale di farmaci scarsamente solubili in acqua, attraverso lo sviluppo di approcci tecnologici per la …

    milano Repository record for NANOSUSPENSIONS-BASED ORAL DELIVERY PLATFORMS - NANODPS (opens in a new tab)